Biotech firm Ayoxxa Biosystems unveils Lunaris Human 12-Plex Th17 Kit
Category: #health  By Saif Ali Bepari  Date: 2018-04-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biotech firm Ayoxxa Biosystems unveils Lunaris Human 12-Plex Th17 Kit

The Germany headquartered biotechnology firm Ayoxxa Biosystems GmbH has apparently announced the expansion of its product portfolio by launching Lunaris Human 12-Plex Th17 Kit. The company, which is known to provide an assortment of services and products related to translational proteomics, now intends to offer a wholly scalable multiplex protein analysis with the new kit.

As per reliable sources, the latest kit would complement the company’s existing Lunaris Mouse 12-Plex Th17 Kit and would provide measurable authentication of soluble pro-inflammatory Th17 cell-associated markers. Apparently, the combination of both the kits would assist scientists to study the effects of Th17 cell activation on immune-mediated illnesses from mouse model to clinical research by utilizing a single validated platform. Moreover, the integration of both the kits would assist scientists to initiate comparative research on Th17 cell activation, cite reliable sources.

Speaking on the firm’s latest launch, CEO of Ayoxxa, Rodney Turner was quoted stating that the increasing portfolio of disease-associated panels such as the new Lunaris Kits would fuel the understanding of intricate biological mechanisms which shall further lead to the development of biomarker signatures. He was further quoted stating that the new kit would profoundly aid researchers in analyzing illness-related biomarkers and monitor the outcomes from laboratory models to human clinical trials.

According to trusted sources, the latest kits have been enhanced to run on the firm’s flagship multiplex protein analysis system Lunaris. The system consists of the state-of-the-art Lunaris software for image-based analysis and a dedicated Lunaris reader. The freshly introduced Lunaris Human 12-Plex Th17 Kit has also been said to assist researchers in studying immune and inflammation response.

For the record, Lunaris is a highly optimized automated system that provides standardized workflow from sample to result. The system can further be seamlessly integrated into any lab routine, cite reliable sources.



About Author

Saif Ali Bepari

Email: [email protected]   

Saif Ali Bepari

Saif Ali Bepari currently works a content writer for Market Size Forecasters, Algosonline, and numerous other platforms. A Computer Science graduate who has a zest for writing over coding, he has previously dabbled into technical and creative writing. He now pens down...

Read More

More News By Saif Ali Bepari

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Saif Ali Bepari

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Saif Ali Bepari

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
By Saif Ali Bepari

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patient...